Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis

[1]  D. Rossi,et al.  Dysregulation of Astrocytic HMGB1 Signaling in Amyotrophic Lateral Sclerosis , 2018, Front. Neurosci..

[2]  T. Woodruff,et al.  Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis , 2018, Journal of Neuroinflammation.

[3]  Huan Yang,et al.  High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. , 2018, Seminars in immunology.

[4]  U. Andersson,et al.  Neuroinflammation in Response to Intracerebral Injections of Different HMGB1 Redox Isoforms , 2018, Journal of Innate Immunity.

[5]  Huan Yang,et al.  Extracellular HMGB1 as a therapeutic target in inflammatory diseases , 2018, Expert opinion on therapeutic targets.

[6]  John D. Lee,et al.  Defects in synaptic transmission at the neuromuscular junction precede motor deficits in a TDP‐43Q331K transgenic mouse model of amyotrophic lateral sclerosis , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  B. Barres,et al.  Microglia and macrophages in brain homeostasis and disease , 2017, Nature Reviews Immunology.

[8]  Giancarlo Logroscino,et al.  Erratum: Amyotrophic lateral sclerosis (Nature reviews. Disease primers (2017) 3 (17071)) , 2017 .

[9]  D. Offen,et al.  Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model , 2017, International journal of molecular sciences.

[10]  F. Michetti,et al.  The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches , 2017, Front. Aging Neurosci..

[11]  P. Freskgård,et al.  Antibody therapies in CNS diseases , 2017, Neuropharmacology.

[12]  T. Woodruff,et al.  Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis , 2017, Skeletal Muscle.

[13]  T. Woodruff,et al.  Pharmacological inhibition of complement C5a‐C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis , 2017, British journal of pharmacology.

[14]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[15]  R. Robitaille,et al.  New perspectives on amyotrophic lateral sclerosis: the role of glial cells at the neuromuscular junction , 2016, The Journal of physiology.

[16]  K. Tracey,et al.  A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug‐induced liver injury and postinjury inflammation in mice , 2016, Hepatology.

[17]  Faith H. Brennan,et al.  Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. , 2016, Seminars in immunology.

[18]  A. Schmidt,et al.  Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice , 2016, Front. Cell. Neurosci..

[19]  J. Juranek,et al.  RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis , 2016, Neuroscience & Biobehavioral Reviews.

[20]  P. Limburg,et al.  Treatment with Anti-HMGB1 Monoclonal Antibody Does Not Affect Lupus Nephritis in MRL/lpr Mice , 2016, Molecular medicine.

[21]  Sara Zarei,et al.  A comprehensive review of amyotrophic lateral sclerosis , 2015, Surgical neurology international.

[22]  K. Thompson,et al.  A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS. , 2015, Journal of visualized experiments : JoVE.

[23]  S. Phipps,et al.  Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis , 2015, Journal of Neuroinflammation.

[24]  K. Tracey,et al.  DAMP Signaling is a Key Pathway Inducing Immune Modulation after Brain Injury , 2015, The Journal of Neuroscience.

[25]  J. Rothstein,et al.  Glial cells in amyotrophic lateral sclerosis , 2014, Experimental Neurology.

[26]  S. Bates,et al.  Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis. , 2014, Human molecular genetics.

[27]  D. Brites,et al.  Microglia centered pathogenesis in ALS: insights in cell interconnectivity , 2014, Front. Cell. Neurosci..

[28]  T. Woodruff,et al.  Role for terminal complement activation in amyotrophic lateral sclerosis disease progression , 2013, Proceedings of the National Academy of Sciences.

[29]  T. Woodruff,et al.  Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis , 2013, Journal of Neuroinflammation.

[30]  V. Pavlov,et al.  HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6Chigh inflammatory monocytes in murine sepsis survivors , 2013, Journal of internal medicine.

[31]  G. Forloni,et al.  Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration , 2012, Molecular medicine.

[32]  A. Ohtsuka,et al.  Anti–high mobility group box‐1 antibody therapy for traumatic brain injury , 2012, Annals of neurology.

[33]  S. Przedborski,et al.  The Role of the Innate Immune System in ALS , 2012, Front. Pharmacol..

[34]  M. Schachner,et al.  HMGB1 in Development and Diseases of the Central Nervous System , 2012, Molecular Neurobiology.

[35]  L. Varani,et al.  HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 , 2012, The Journal of experimental medicine.

[36]  U. Andersson,et al.  Monoclonal Anti-HMGB1 (High Mobility Group Box Chromosomal Protein 1) Antibody Protection in Two Experimental Arthritis Models , 2011, Molecular medicine.

[37]  E. Aronica,et al.  Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue , 2011, Neuroscience.

[38]  P. Mccombe,et al.  The Role of Immune and Inflammatory Mechanisms in ALS , 2011, Current molecular medicine.

[39]  W. Robberecht,et al.  Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease , 2011, The Lancet Neurology.

[40]  S. Akira,et al.  A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release , 2010, Proceedings of the National Academy of Sciences.

[41]  Fred H. Gage,et al.  Mechanisms Underlying Inflammation in Neurodegeneration , 2010, Cell.

[42]  P. Monk,et al.  The Complement Factor C5a Contributes to Pathology in a Rat Model of Amyotrophic Lateral Sclerosis1 , 2008, The Journal of Immunology.

[43]  K. Tracey,et al.  The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage , 2008, The Journal of Neuroscience.

[44]  E. Abraham,et al.  HMGB1 Develops Enhanced Proinflammatory Activity by Binding to Cytokines1 , 2008, The Journal of Immunology.

[45]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[46]  S. Hochman.  THE SPINAL CORD , 2007 .

[47]  C. Bendotti,et al.  Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS , 2007, Neuroscience Letters.

[48]  V. Meininger,et al.  Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[49]  Jong-sang Park,et al.  HMGB1, a Novel Cytokine-Like Mediator Linking Acute Neuronal Death and Delayed Neuroinflammation in the Postischemic Brain , 2006, The Journal of Neuroscience.

[50]  T. Heiman-Patterson,et al.  Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. , 2004, Brain research. Molecular brain research.

[51]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.